Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality.

What was studied

This is a guideline for low blood counts in myelofibrosis. Low blood counts, called cytopenias, are common, mostly anemia. Few good treatments exist. Portugal has no national guidance. A panel of hematologists set out an approach for Portuguese practice. It draws on evidence and clinical experience.

What they found

First, the cause of the anemia should be found. With an enlarged spleen or body symptoms, Janus kinase inhibitors come first. The choices are momelotinib alone or ruxolitinib with another drug. Without those signs, options include an agent that boosts red cell making, danazol or momelotinib. With low platelets, ruxolitinib at a reduced dose or momelotinib may be used. Transfusion may be considered in severe anemia, low platelets, bleeding or surgery.

What it means for patients

The authors said using this approach will help optimize care for these patients. They said it will improve clinical outcomes. They said response means better symptoms and a smaller spleen. It also means less need for transfusion. They said switching treatment is warranted if the drug fails, causes toxicity or loses effect.

Why it is not certain yet

This is an expert panel approach, not a trial. It rests on evidence and clinical experience. The abstract gives no trial data. The approach is adapted to practice in Portugal.

Source

Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality.

We restate facts from the source record in our own words. The original wording belongs to its publisher.